Published in Radiother Oncol on March 27, 2006
Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 2.48
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer (2010) 2.04
Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.99
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer (2010) 1.42
Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys (2011) 1.34
Assessment of post-radiotherapy salivary glands. Br J Radiol (2011) 1.26
Organ-sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol (2011) 0.99
Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy. Radiat Oncol (2011) 0.89
Submandibular gland sparing in intensity-modulated radiotherapy for N0-stage nasopharyngeal carcinoma. Br J Radiol (2014) 0.87
Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiat Oncol (2014) 0.84
Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control. Radiat Oncol (2013) 0.83
Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. BMC Cancer (2015) 0.82
Parotid gland volumetric changes during intensity-modulated radiotherapy in head and neck cancer. Br J Radiol (2012) 0.82
Erratum to "Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer" [Radiother. Oncol. 78 (2006) 270-275]. Radiother Oncol (2006) 0.81
Long-term results of ipsilateral radiotherapy for tonsil cancer. Radiat Oncol J (2013) 0.80
Human adipose tissue‑derived stem cells alleviate radiation‑induced xerostomia. Int J Mol Med (2014) 0.79
Health-related quality of life of head and neck cancer patients with successful oncological treatment. Eur Arch Otorhinolaryngol (2014) 0.78
Sparing submandibular gland by IMRT. Radiother Oncol (2006) 0.78
Normal tissue complication probability model parameter estimation for xerostomia in head and neck cancer patients based on scintigraphy and quality of life assessments. BMC Cancer (2012) 0.78
Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.77
IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res (2016) 0.75
The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels. Radiat Oncol (2017) 0.75
Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy. Eur Arch Otorhinolaryngol (2015) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst (2009) 3.17
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol (2011) 2.78
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol (2004) 2.61
Testing of the analytical anisotropic algorithm for photon dose calculation. Med Phys (2006) 2.59
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology (2006) 2.50
Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol (2007) 2.17
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009) 2.16
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol (2005) 1.82
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol (2008) 1.69
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Taxanes and anthracyclines in early breast cancer: which first? Lancet Oncol (2010) 1.53
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol (2008) 1.46
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res (2011) 1.44
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
Diffusion-weighted MR imaging in normal human brains in various age groups. AJNR Am J Neuroradiol (2002) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst (2013) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res (2004) 1.35
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest (2014) 1.33
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res (2008) 1.33
Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res (2003) 1.31
Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res (2012) 1.29
Acceptance tests and quality control (QC) procedures for the clinical implementation of intensity modulated radiotherapy (IMRT) using inverse planning and the sliding window technique: experience from five radiotherapy departments. Radiother Oncol (2002) 1.25
Elective neck treatment versus observation in patients with T1/T2 N0 squamous cell carcinoma of oral tongue. Oral Oncol (2005) 1.24
High-resolution CT by diffraction-enhanced x-ray imaging: mapping of breast tissue samples and comparison with their histo-pathology. Phys Med Biol (2007) 1.23
Suicide after breast cancer: an international population-based study of 723,810 women. J Natl Cancer Inst (2006) 1.23
Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol (2013) 1.21
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst (2007) 1.20
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov (2013) 1.17
Phase-contrast X-ray imaging of breast. Acta Radiol (2010) 1.15
Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat (2007) 1.15
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging. Magn Reson Med (2002) 1.13
Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology (2004) 1.11
Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One (2008) 1.10
Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med (2003) 1.10
T1/T2*-weighted MRI provides clinically relevant pseudo-CT density data for the pelvic bones in MRI-only based radiotherapy treatment planning. Acta Oncol (2012) 1.09
Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol (2008) 1.08
Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol (2002) 1.08
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood (2004) 1.07
Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol (2004) 1.07
VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell (2008) 1.07
The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol (2008) 1.07
MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol (2005) 1.06
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat (2005) 1.06
Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain (2002) 1.06
Surgical treatment in Paget's disease of the breast. Am J Surg (2010) 1.05
Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2004) 1.03
High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.02
Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys (2011) 1.01
Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. Cancer Epidemiol (2010) 1.00
Axillary and supraclavicular recurrences are rare after axillary lymph node dissection in breast cancer. World J Surg (2012) 1.00
Protection from radiation-induced male germ cell loss by sphingosine-1-phosphate. Biol Reprod (2003) 1.00
Predictive value of histopathologic parameters in early squamous cell carcinoma of oral tongue. Oral Oncol (2007) 0.99
How can a cost/benefit ratio be optimized for an output measurement program of external photon radiotherapy beams? Phys Med Biol (2011) 0.98
Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant (2009) 0.97
Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res (2005) 0.97
Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res (2003) 0.97
Tamoxifen therapy for patients with breast cancer. Lancet (2013) 0.96
Human breast cancer in vitro: matching histo-pathology with small-angle x-ray scattering and diffraction enhanced x-ray imaging. Phys Med Biol (2005) 0.96
Localization of local anesthetic solution by magnetic resonance imaging. Ophthalmology (2004) 0.96
Imatinib and altered bone and mineral metabolism. N Engl J Med (2006) 0.95
Pharyngocutaneous fistula following total laryngectomy: a single institution's 10-year experience. Eur Arch Otorhinolaryngol (2006) 0.95
Association of Merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in Merkel cell carcinoma. Int J Cancer (2011) 0.94
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol (2011) 0.94
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res (2009) 0.93
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogenet (2006) 0.92
Analysis of quality control data of eight modern radiotherapy linear accelerators: the short- and long-term behaviours of the outputs and the reproducibility of quality control measurements. Phys Med Biol (2006) 0.92